FITB
58
-10
JBHT
45
-4
EBAY
57
3
PEP
59
-4
CRM
49
4
NSC
68
4
MA
39
-4
IFF
66
4
DOV
50
-5
NEE
54
2
PCG
50
2
OKE
49
4
KMI
42
4
EFX
52
2
TGNA
50
-4
XRAY
35
-2
SIG
46
2
KHC
36
-2
PX
73
-3
PPG
48
-2
FITB
58
-10
JBHT
45
-4
EBAY
57
3
PEP
59
-4
CRM
49
4
NSC
68
4
MA
39
-4
IFF
66
4
DOV
50
-5
NEE
54
2
PCG
50
2
OKE
49
4
KMI
42
4
EFX
52
2
TGNA
50
-4
XRAY
35
-2
SIG
46
2
KHC
36
-2
PX
73
-3
PPG
48
-2
Financhill
Back

Marker Therapeutics 10K Form

Sell
31

MRKR
Marker Therapeutics

Last Price:
$1.70
Seasonality Move:
8.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MRKR News And Ratings

See the #1 stock for the next 7 days that we like better than MRKR

MRKR Financial Statistics

Sales & Book Value

Annual Sales: $6.6M
Cash Flow: $-5.5M
Price / Cash Flow: 0
Annual Sales: $1.29
Price / Book: 1.33

Profitability

EPS (TTM): -1.33000
Net Income (TTM): $-12.8M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Marker Therapeutics Earnings Forecast

Key Marker Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for MRKR have been equal to 64.35% of Gross Profit Margin.
  • The Research & Development expenses have been 204.33% of Revenue.
  • Per Share Earnings over the last 18 years have been positive in 11 years.

Marker Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MRKR
CUSIP: 57055L
Website: markertherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRKR Technical Analysis vs Fundamental Analysis

Sell
31
Marker Therapeutics (MRKR) is a Sell

Is Marker Therapeutics a Buy or a Sell?